click below
click below
Normal Size Small Size show me how
Pharmacology
Normal Lab Findings + Medications
Term | Definition |
---|---|
Glucose | 70-110 (fasting) |
BUN | 8-21 mg/dL |
Creatinine | 0.5-1.2 mg/dL |
Serum Osmolarity | 275-295 |
Total WBC | 4500-11100 |
Neutrophils | Total: 59% 2700-6500 Bands: 3% 100-300 Segmented: 56% 2500-6200 |
Eosinophils | 11yr+ Absolute = 0.05-0.5 percentage = 0-5.5% |
RBC | 4.5-5.3 (men) 4.1-5.1 (women) |
Hemoglobin | 13-17 (men) 12-16 (women) |
Hematocrit | 37-51% (men) 33-46% (women) |
Platelets | 150,000-450,000 |
PTT | 22.1-34.1 seconds (aPTT) 60-90 seconds (PTT) |
PT / INR | PT: 11.2-13.2 seconds (+/- 2) INR: 1-1.4 |
Albumin | 20-40 yr: 3.7-5.1 41-60 yr: 3.4-4.8 61-90 yr: 3.2-4.6 90+ yr: 2.9-4.5 |
Total Cholesterol | Desirable: less than 200 mg/dL Borderline: 200-239 mg/dL HIGH: >240 mg/dL |
HDL-C (high density lipoprotein-calculated) | Recommended: Men > 40 mg/dL Women >50 mg/dL Low CAD Risk: >60 mg/dL High CAD Risk: <40 mg/dL |
Triglycerides (TGs) | Normal: <150 mg/dL Borderline High: 150-199 mg/dL High: 200-499 mg/dL Very High: >500 mg/dL |
LDL-C (low density lipoprotein calculated) | optimal: <100 mg/dL |
Urine Specific Gravity | 1.001-1.029 |
Leukocyte Esterase | Negative |
Urine pH | 5-9 |
Treat isotonic volume contraction with | isotonic (0.9%) sodium chloride OR 0.9% NaCl |
Treat hypertonic volume contraction with | hypotonic (e.g. 0.45% NaCl) |
Treat hypotonic volume contraction with | hypertonic (e.g. 3% NaCl) |
Treat volume expansion with | diuretics |
Treat respiratory or metabolic acidosis with | sodium bicarbonate (NaHCO3) |
Treat respiratory alkalosis by | having patients inhale 5% CO2 or rebreathe their expired air |
Treat metabolic alkalosis with | an infusion of sodium chloride plus potassium chloride. For severe cases, infuse 0.1% hydrochloric acid or ammonium chloride |
Treat moderate hypokalemia with | potassium chloride in sustained-release tablets |
Treat severe hypokalemia with | IV potassium chloride |
To treat hyperkalemia, begin by withdrawing potassium-containing foods and drugs that promote potassium accumulation (e.g., potassium supplements, potassium-sparing diuretics) | Subsequent measures include (1) infusing a calcium salt to offset the cardiac effects of potassium, (2) infusing glucose and insulin to promote potassium uptake by cells, and (3) infusing sodium bicarbonate if acidosis is present |
Treat hypomagnesemia with IM or IV | magnesium sulfate For prophylaxis, give oral magnesium (e.g., magnesium oxide) |
Diabetes is characterized by | sustained hyperglycemia |
Initial metabolic changes involve | glucose and other carbohydrate. If the disease progresses, metabolism of fats and proteins changes as well |
Diabetes has two major forms: | type I and type II |
Symptoms of type I result from a | complete absence of insulin the underlying cause is autoimmune destruction of pancreatic beta cells |
Early in the disease process, symptoms of type II diabetes result mainly from | cellular resistance to insulin's actions, not from insulin deficiency HOWEVER, later in the disease process, insulin deficiency develops |
Type I and type II diabetes share the same long-term complications of: | heart disease stroke blindness renal failure neuropathy lower limb amputations erectile dysfunction gastroparesis |
Diabetes is diagnosed if | (1) hemoglobin A1C is 6.5% or higher (2) fasting plasma glucose is 126 mg/dL or higher, (3) an oral glucose tolerance test (OGTT) results in a blood glucose of 200 mg/dL or higher; or the patient presents with classic symptoms of hyperglycemia |
With both type I and type II diabetes, the goal of treatment is to | manage symptoms of hyperglycemia and reduce long-term complications including death |
type I diabetes is treated primarily with | insulin replacement |
type II diabetes is treated with | oral antidiabetic drugs (e.g., metformin) or, if needed, with insulin or non-insulin injectable drugs--but always in conjunction with diet modification and exercise |